Vivaglobin Market Report 2026

Vivaglobin Market Overview

• The Vivaglobin market growth in the historic period has been driven by improved diagnosis rates of primary immunodeficiency disorders, increased clinical acceptance of SCIg therapies • Market expansion is supported by rising demand for self-administered immunoglobulin treatments, expansion of personalized immunotherapy approaches • Growth Driver: Impact Of Primary Immunodeficiency Prevalence On The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vivaglobin Market?

Vivaglobin is a subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiency (PI), a group of disorders that impair the immune system's ability to fight infections. It provides a steady supply of antibodies to help boost the immune system and protect against recurrent infections. The main types of indications for vivaglobin are primary immune deficiency (PID), secondary immune deficiency (SID), chronic inflammatory demyelinating polyneuropathy (CIDP), and other indications. Primary immune deficiency (PID) is a group of genetic disorders resulting in a compromised immune system that decreases the body's ability to fight infections. They are distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and are used by several end users, including adults, geriatric patients, and pediatric patients.

What Is The Vivaglobin Market Growth Forecast?

The growth in the forecast period can be attributed to rising demand for self-administered immunoglobulin treatments, expansion of personalized immunotherapy approaches, increasing investment in rare disease treatment pipelines, growing geriatric population with immune disorders, advancements in plasma fractionation technologies. Major trends in the forecast period include increasing adoption of subcutaneous immunoglobulin therapies, rising preference for home-based treatment administration, growing focus on long-term immune replacement therapies, expansion of patient-centric dosing solutions, enhanced emphasis on treatment safety and tolerability.

Global Vivaglobin Market Segmentation

1) By Indication: Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 3) By End User: Adult, Geriatric, Pediatric

What Are The Drivers Of The Vivaglobin Market?

The rising prevalence of primary immunodeficiency diseases (PI) is significantly driving the growth of the vivaglobin market in the future. Primary immunodeficiency diseases refer to a group of disorders where the immune system is deficient or absent, impairing the body's ability to fight infections and leading to increased susceptibility to illnesses. The increasing prevalence of Primary Immunodeficiency Diseases (PI) is due to factors such as advancements in diagnostic techniques, greater awareness and recognition of these conditions, improved genetic testing, and the better identification of previously undiagnosed cases. Vivaglobin helps primary immunodeficiency diseases by providing a consistent supply of antibodies through subcutaneous administration, enhancing the immune system's ability to combat infections and reducing the frequency and severity of recurrent illnesses in affected patients. For instance, in August 2023, according to a report published by Thermo Fisher, a US-based life science and clinical research company, it was reported that around 6 million people worldwide are estimated to have a PID. It is estimated that about 5,000 individuals within the UK suffer from PID disorder. Therefore, rising prevalence of Primary Immunodeficiency Diseases (PI) is expected to drive the growth of the vivaglobin industry. The increasing investment in research and development is expected to fuel the vivaglobin market growth going forward. Research and development in medicine involves the systematic investigation of new drugs, treatments, or medical technologies to advance healthcare. It includes clinical trials, laboratory experiments, and regulatory processes to ensure safety and efficacy. Increasing R&D in medicine enhances the discovery of innovative treatments, improves patient outcomes, and addresses emerging health challenges. Increasing research and development supports vivaglobin by driving innovations in immunoglobulin formulations, improving administration methods, and enhancing treatment efficacy and accessibility for patients with primary immunodeficiency diseases. For instance, in April 2025, according to The Office for National Statistics (ONS), a UK-based producer of official statistics, the UK government’s net R&D spend increased by 8.2% year-on-year, rising from £16.1 billion in 2022 to £17.4 billion in 2023. Therefore, the increasing investment in research and development is driving the growth of the vivaglobin industry. The increasing geriatric population is set to propel the growth of the vivaglobin market moving forward. The geriatric population typically refers to older adults, usually aged 65 and over, who often face unique health, social, and economic challenges. The increasing geriatric population is primarily due to advancements in healthcare, leading to longer life expectancy and declining birth rates. Vivaglobin supports the geriatric population by providing a convenient and effective subcutaneous immunoglobulin therapy that strengthens the immune system, reducing the risk of infections and improving overall quality of life in older adults with weakened immunity or primary immunodeficiency diseases. For instance, in May 2024, according to the Administration for Community Living, a US-based government agency, in 2022, 17.3% of the population was 65 or older. This percentage is expected to increase to 22% by 2040. Therefore, the increasing geriatrics is driving the growth of the vivaglobin industry.

Key Players In The Global Vivaglobin Market

Major companies operating in the vivaglobin market are CSL Behring GmbH

Regional Insights

North America was the largest region in the vivaglobin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vivaglobin Market?

The vivaglobin market consists of sales of intravenous immunoglobulin (IVIG) products, subcutaneous immunoglobulin (SCIG) formulations, and hyperimmune globulin therapies. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vivaglobin Market Report 2026?

The vivaglobin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vivaglobin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.